

10/564854

Docket No. 281259US0PCT

IAP20 Rec'd PCT/PTO 17 JAN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Angelo GUGLIELMOTTI, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/EP04/07635

GAU:

FILED: Herewith

EXAMINER:

FOR: USE OF INDAZOLE DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

281259US0PCT

SERIAL NO. 64854  
New U.S. PCT Application  
Based on PCT/EP04/07635

## LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Angelo GUGLIELMOTTI, et al.

FILING DATE

Herewith

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,817,676	10/6/98	CATLOW, John T. et al.			
	AB						
	AC						
	AD						
	AE						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF	0 975 623	2/2/00	EP		No
	AG	93/03725	3/4/93	WO		No
	AH	2004/014922	2/19/04	WO		No
	AI					
	AJ					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AJ	DOAK, G.J.; SAWYNOK, J.: "Formalin-Induced Nociceptive Behavior and Edema: Involvement of Multiple Peripheral 5-Hydroxytryptamine Receptor Subtypes" NEUROSCIENCE, Vol. 80, No. 3, 1997, Pages 939-949, XP002279566
	AK	DONAHUE, et al.: "Electrolytic Lesion of the Anterior Cingulate Cortex Decreases Inflammatory, but not Neuropathic Nociceptive Behavior in Rats" BRAIN RESEARCH, Vol. 897, No. 1-2, 2001, Pages 131-138, XP002279567
	AL	BEERS, M. and BERKOW, R.: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition" 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002279568, Page 1371-1372
	AM	ESPEJOE, et al.: "Antagonism of Peripheral 5-HT <sub>4</sub> Receptors Reduces Visceral and Cutaneous Pain in Mice, and Induces Visceral Analgesia After Simultaneous Inactivation of 5-HT <sub>3</sub> Receptors" BRAIN RESEARCH, Amsterdam, NL; Vol. 788, No. 1/2, 1998, Pages 20-24 XP001064161
	AN	TORSELL, Kurt et al., "Isolation, Structure and Synthesis of Alkaloids From Valeriana Officinalis L", Acta Chemica Scandinavica 21 (1), Pages 53-62, 1967
	AO	ASHBURN, Michael A., STAATS, Peter S.: "Management of Chronic Pain", THE LANCET, Vol. 353, Pages 1865-69, 1999
	AP	BANNON, A.W., et al.: "ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain", BRAIN RESEARCH, Vol. 801, Pages 158-63, 1998
	AQ	BENNETT, Gary J. and XIE, Y.K.: "A Peripheral Mononeuropathy in Rat that Produces Disorders of Pain Sensation Like Those Seen in Man", PAIN, 33, Pages 87-107, 1988
	AR	COURTEIX, C., ESCHALIER, A., and LAVARENNE, J.: "Streptozocin-Induced Diabetic Rats: Behavioural Evidence for a Model of Chronic Pain", PAIN, 53, Pages 81-88, 1993
	AS	SCHOLZ, J. and WOOLF, C.J.: "Can We Conquer Pain?", NATURE NEUROSCIENCE, Volume 5, Pages 1062-1067, November 2002
	AT	SELTZER, Z. et al.: "A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury", PAIN, 43, Pages 205-218, 1990
	AU	WOOLF, Clifford J. et al.: "Neuropathic Pain: Aetiology, Symptoms, Mechanisms, and Management", THE LANCET, Vol. 353, Pages 1959-1964, June 5, 1999
	AV	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

New U.S. PCT Application based on PCT/EP04/07635  
Docket No. 281259US0PCT

STATEMENT OF RELEVANCY

1) References AA, AF-AH and AJ-AM have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.

2) References \_\_\_\_\_ have been cited in the corresponding \_\_\_\_\_ Search Report. A copy of these references is being submitted herewith.

3) References AN-AU are discussed in the specification. A copy of these references is being submitted herewith.

4) References \_\_\_\_\_ are additional prior art known to Applicant. A copy of these references is being submitted herewith.